Healthcare Feb 08, 2022 09:25 AM (GMT+8) · EqualOcean
Recently, Yousen Jianheng biomedical (Shanghai) Co., Ltd. announced that it had completed more than 200 million yuan of round a financing. This round of financing is led by Shenzhen shared investment, followed by Zhangjiang Haoheng and Yingke capital. The original shareholders continue to participate in this round of investment. The raised funds will be used to carry out and accelerate the domestic and foreign clinical trials of ua007 and ua021, the research and development of small molecule drugs with multiple new targets and the development of specific double antibody drugs. Yousen Jianheng is an innovative drug enterprise committed to the research and development of first in class / best in class drugs. It focuses on cancer and autoimmune diseases, targeting difficult drug targets and key oncogenes. The R & D pipeline includes small molecule targeted drugs, recombinant proteins and single / double antibody drugs. The company's core team has served as executives in multinational pharmaceutical enterprises and domestic cro leading enterprises, and has rich experience in the field of innovative drug R & D. At present, the company's ua007 project has carried out a clinical phase II (prevention and treatment of CID) and a clinical phase I study (treatment of acute gout) in China. Ua021, a small molecule targeting drug for autoimmune diseases, is in the ind enabling stage and is expected to carry out global clinical trials in 2022.

This text is a result of machine translation.